Skip to content
akaturk Academic measurement
Sign in Sign up

Article detail · 2023

Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

Journal

The Lancet
OpenAlex Open access · bronze SJR Q1 JCR Q1 Citations 200 Top 1% Percentile 99.7% FWCI 29.1
Year
2023
DOI
10.1016/s0140-6736(23)02408-x
Type
article

Data source split

  • YÖKSİS venue The Lancet
  • OpenAlex OpenAlex enrichment (abstract, citations, topics)

OpenAlex record

Abstract

Abstract not compiled yet; it will appear after the DergiPark / OpenAlex queue runs.

Topics

Citations

OpenAlex cited_by_count. Not a WoS or Scopus citation count; those sources have no separate column here.

200 citations

OpenAlex cited_by_count (cache / database)

4 publications in the local catalog that cite this work (OpenAlex reference match; not the full global list).

  1. Balcinrenone in combination with dapagliflozin compared with dapagliflozin alone in patients with chronic kidney disease and albuminuria: a randomised, active-controlled double-blind, phase 2b clinical trial 2025 Citations 19 · OpenAlex
  2. CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes 2025 Citations 17 · OpenAlex
  3. CVOT Summit Report 2025: advances along the cardiovascular–kidney–metabolic disease continuum 2026 Citations 3 · OpenAlex
  4. The evolving field of nephrology: what comes next? A report from the European Renal Association Scientific Advisory Board 2026 Citations 1 · OpenAlex

Authors

No author information.